Search Within

MYELODYSPLASTIC SYNDROMES
Results 1 - 65 of 65
Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes and Myeloid Leukemia

Journal: Current Cancer Drug Targets
Volume: 11,Issue: 7
Page: 837-848
Authors: Anna Szmigielska-Kaplon and Tadeusz Robak

Fractal Analysis of the Bone Marrow in Myelodysplastic Syndromes

Journal: Current Bioinformatics
Volume: 9,Issue: 4
Page: 408-413
Authors: Giorgio Bianciardi and Pietro Luzi

Biologic Characteristics of Bone Marrow Mesenchymal Stem Cells in Myelodysplastic Syndromes

Journal: Current Stem Cell Research & Therapy
Volume: 6,Issue: 2
Page: 122-130
Authors: Maria-Christina Kastrinaki, Charalampos Pontikoglou, Mirjam Klaus, Emily Stavroulaki, Konstantia Pavlaki and Helen A. Papadaki

Myelodysplastic Syndromes: Review of Pathophysiology and Current Novel Treatment Approaches

Journal: Current Cancer Drug Targets
Volume: 7,Issue: 6
Page: 541-558
Authors: E. D. Warlick and B. D. Smith

Biological Basis of Novel Therapies for Myelodysplastic Syndrome

Journal: Current Cancer Therapy Reviews
Volume: 2,Issue: 3
Page: 199-209
Authors: Eyal C. Attar and Karen K. Ballen

Utility of DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndromes

Journal: Current Pharmaceutical Design
Volume: 18,Issue: 22
Page: 3190-3197
Authors: Kaoru Tohyama

Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes

Journal: Current Pharmaceutical Design
Volume: 23,Issue: 1
Page: 135-169
Authors: Karmen Stankov, Suncica Stankov and Jasmina Katanic

Nuclear PI-PLCβ1 and Myelodysplastic Syndromes: Genetics and Epigenetics

Journal: Current Pharmaceutical Design
Volume: 18,Issue: 13
Page: 1751-1754
Authors: Matilde Y. Follo, Sara Mongiorgi, Carlo Finelli, Manuela Piazzi, Irene Faenza, Giulia Ramazzotti, Patrizia Santi, James A. McCubrey, Alberto M. Martelli and Lucio Cocco

Genome-wide Analysis of Myelodysplastic Syndromes

Journal: Current Pharmaceutical Design
Volume: 18,Issue: 22
Page: 3163-3169
Authors: Masashi Sanada and Seishi Ogawa

Lenalidomide for Treatment of Myelodysplastic Syndromes

Journal: Current Pharmaceutical Design
Volume: 18,Issue: 22
Page: 3198-3203
Authors: Rami S. Komrokji and Alan F. List

Immunosuppressive Therapy for Myelodysplastic Syndromes

Journal: Current Pharmaceutical Design
Volume: 18,Issue: 22
Page: 3184-3189
Authors: Christiane Dobbelstein and Arnold Ganser

Drug Resistance and Methylation in Myelodysplastic Syndrome

Journal: Current Pharmaceutical Biotechnology
Volume: 8,Issue: 2
Page: 77-81
Authors: D. O. Vidal, L. F. Lopes and E. T. Valera

Antiangiogenesis in Myelodysplastic Syndrome

Journal: Current Cancer Drug Targets
Volume: 11,Issue: 9
Page: 1044-1052
Authors: A. Aguayo, F. M. Armillas-Canseco and D. Martinez-Banos

World Health Organization Classification of Myelodysplastic Syndromes

Journal: Current Pharmaceutical Design
Volume: 18,Issue: 22
Page: 3149-3162
Authors: Magdalena Czader and Attilio Orazi

MicroRNA Dysregulation in the Myelodysplastic Syndromes

Journal: MicroRNA
Volume: 2,Issue: 3
Page: 174-186
Authors: Stephen S. Chung and Christopher Y. Park

Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes

Journal: Current Pharmaceutical Design
Volume: 22,Issue: 16
Page: 2333-2344
Authors: Bon Ham Yip, Hamid Dolatshad, Swagata Roy, Andrea Pellagatti and Jacqueline Boultwood

Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes

Journal: Current Pharmaceutical Design
Volume: 22,Issue: 16
Page: 2349-2357
Authors: Carlo Finelli, Matilde Y. Follo, Marta Stanzani, Sarah Parisi, Cristina Clissa, Sara Mongiorgi, Marilena Barraco and Lucio Cocco

The Interactions Between Diabetes Mellitus and Myelodysplastic Syndromes: Current State of Evidence and Future Directions

Journal: Current Diabetes Reviews
Volume: 12,Issue: 3
Page: 231-239
Authors: Eyad Hamoudeh, Amer M. Zeidan, Lisa Barbarotta and Nina Rosano

Implications of Somatic Mutations in the AML1/RUNX1 Gene in Myelodysplastic Syndrome (MDS): Future Molecular Therapeutic Directions for MDS

Journal: Current Cancer Drug Targets
Volume: 6,Issue: 6
Page: 553-563
Authors: Hironori Harada, Yuka Harada and Akiro Kimura

Strategies for Biology- and Molecular-Based Treatment of Myelodysplastic Syndromes

Journal: Current Drug Targets
Volume: 6,Issue: 6
Page: 713-725
Authors: E. H. Lindberg

Single Autosomal Trisomy in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Journal: Current Genomics
Volume: 1,Issue: 2
Page: 153-173
Authors: S. K. Ma and T. S.K. Wan

Cytogenetic and Molecular Abnormalities in Myelodysplastic Syndrome

Journal: Current Molecular Medicine
Volume: 11,Issue: 8
Page: 678-685
Authors: H. Nagoshi, S. Horiike, J. Kuroda and M. Taniwaki

Significance of Genome-Wide Analysis of Copy Number Alterations and UPD in Myelodysplastic Syndromes using Combined CGH – SNP Arrays

Journal: Current Medicinal Chemistry
Volume: 19,Issue: 22
Page: 3739-3747
Authors: Ausaf Ahmad and M. Anwar Iqbal

How Recent Advances in High-risk Myelodysplastic Syndrome Physiopathology May Impact Future Treatments

Journal: Current Pharmaceutical Design
Volume: 19,Issue: 30
Page: 5362-5373
Authors: Thomas Cluzeau, Guillaume Robert, Arnaud Jacquel and Patrick Auberger

Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy

Journal: Mini-Reviews in Medicinal Chemistry
Volume: 14,Issue: 11
Page: 873-883
Authors: Lucia Manzoli, Sara Mongiorgi, Cristina Clissa, Carlo Finelli, Anna Maria Billi, Alessandro Poli, Marilisa Quaranta, Lucio Cocco and Matilde Y. Follo

Evaluation of a Bone Marrow Dysmyelopoiesis Immunophenotypic Index for the Diagnosis and Prognosis of Myelodysplastic Syndromes

Journal: Cardiovascular & Hematological Disorders-Drug Targets
Volume: 15,Issue: 2
Page: 148-161
Authors: Evgenia Verigou, Polixeni Lampropoulou, Nikoletta Smyrni, Georgia Kolliopoulou, George Sakellaropoulos, Ioannis Starakis, Panagiotis Zikos, Elena Solomou, Argiris Symeonidis and Marina Karakantza

Immunomodulatory Drugs (IMiDs™): A New Treatment Option for Myelodysplastic Syndromes

Journal: Current Pharmaceutical Biotechnology
Volume: 7,Issue: 5
Page: 339-342
Authors: Vishakha Kale and Alan F. List

Epigenetic Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemias

Journal: Current Medicinal Chemistry
Volume: 15,Issue: 13
Page: 1274-1287
Authors: Giuseppe Leone, Francesco D'Alo, Giuseppe Zardo, Maria Teresa Voso and Clara Nervi

Editorial [Hot Topic: New Treatment Strategy of the Myelodysplastic Syndromes]

Journal: Current Pharmaceutical Design
Volume: 18,Issue: 22
Page: 3147-3148
Authors: Kaoru Tohyama

Review: Recent Clinical Trials in Epigenetic Therapy

Journal: Reviews on Recent Clinical Trials
Volume: 1,Issue: 2
Page: 169-182
Authors: Yasuhiro Oki and Jean-Pierre J. Issa

Clinical Advances in Hypomethylating Agents Targeting Epigenetic Pathways

Journal: Current Cancer Drug Targets
Volume: 10,Issue: 5
Page: 539-545
Authors: S. Cang, Q. Lu, Y. Ma and D. Liu

Update on MDS Therapy: From Famine to Feast

Journal: Cardiovascular & Hematological Agents in Medicinal Chemistry
Volume: 8,Issue: 4
Page: 187-198
Authors: Preeti Chaudhary and Chirag Shah

Implication of microRNAs in the Pathogenesis of MDS

Journal: Current Pharmaceutical Design
Volume: 18,Issue: 22
Page: 3170-3179
Authors: Jing Fang, Melinda Varney and Daniel T. Starczynowski

Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation

Journal: Current Pharmaceutical Design
Volume: 22,Issue: 16
Page: 2345-2348
Authors: Sara Mongiorgi, Matilde Y. Follo, Yong Ryoul Yang, Stefano Ratti, Lucia Manzoli, James A. McCubrey, Anna Maria Billi, Pann-Ghill Suh and Lucio Cocco

5q- syndrome

Journal: Current Pharmaceutical Design
Volume: 18,Issue: 22
Page: 3180-3183
Authors: Jacqueline Boultwood, Andrea Pellagatti and James S. Wainscoat

Current Status of Allogeneic Hematopoietic Cell Transplantation for MDS

Journal: Current Pharmaceutical Design
Volume: 18,Issue: 22
Page: 3215-3221
Authors: Feng Xu and H. Joachim Deeg

Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS

Journal: Current Pharmaceutical Design
Volume: 18,Issue: 22
Page: 3222-3234
Authors: Norbert Gattermann

Demethylating Agents as Epigenetic Anticancer Therapeutics

Journal: Current Cancer Therapy Reviews
Volume: 9,Issue: 1
Page: 24-33
Authors: Arash Nabbi, Shankha Satpathy and Karl Riabowol

Novel Immunosuppressive Strategies for Bone Marrow Failure Syndromes: A Focus on Alemtuzumab

Journal: Mini-Reviews in Medicinal Chemistry
Volume: 11,Issue: 6
Page: 536-543
Authors: C. Selleri, B. Serio and A. M. Risitano

Cancer Therapy-Induced Residual Bone Marrow Injury: Mechanisms of Induction and Implication for Therapy

Journal: Current Cancer Therapy Reviews
Volume: 2,Issue: 3
Page: 271-279
Authors: Yong Wang, Virginia Probin and Daohong Zhou

Radioimmunotherapy of Non-Hodgkins Lymphomas

Journal: Current Drug Targets
Volume: 7,Issue: 10
Page: 1293-1300
Authors: Bruce D. Cheson

Signaling Through RAS-RAF-MEK-ERK: from Basics to Bedside

Journal: Current Medicinal Chemistry
Volume: 14,Issue: 5
Page: 601-623
Authors: Armin Zebisch, Armin P. Czernilofsky, Gyorgy Keri, Julja Smigelskaite, Heinz Sill and Jakob Troppmair

Antiangiogenic Therapy in Hematologic Malignancies

Journal: Current Pharmaceutical Design
Volume: 10,Issue: 11
Page: 1221-1234
Authors: Moehler T. M., Hillengass J., Goldschmidt H. and Ho A. D.

Inhibition of Raf Kinase in the Treatment of Acute Myeloid Leukemia

Journal: Current Pharmaceutical Design
Volume: 8,Issue: 25
Page: 2243-2248
Authors: Michael Crump

Development of DNA Methyltransferase Inhibitors for the Treatment of Neoplastic Diseases

Journal: Current Medicinal Chemistry
Volume: 16,Issue: 17
Page: 2075-2085
Authors: Tamer E. Fandy


Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications

Journal: Current Pharmaceutical Design
Volume: 22,Issue: 16
Page: 2323-2332
Authors: Anna Mies, Ekaterina Bulycheva, Inga Mandac Rogulj, Lorenz C. Hofbauer and Uwe- Platzbecker

The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors

Journal: Mini-Reviews in Medicinal Chemistry
Volume: 16,Issue: 16
Page: 1344-1358
Authors: Jiao Chen, Jie Yang and Peng Cao

Development of WT1 Peptide Cancer Vaccine Against Hematopoietic Malignancies and Solid Cancers

Journal: Current Medicinal Chemistry
Volume: 13,Issue: 20
Page: 2345-2352
Authors: Y. Oji, H. Sugiyama, I. Kawase, O. A. Elisseeva, H. Nakajima, K. Udaka, M. Kawakami, A. Tsuboi and Y. Oka

DNA Hypermethylation of Myeloid Cells, A Novel Therapeutic Target in MDS and AML

Journal: Current Pharmaceutical Biotechnology
Volume: 7,Issue: 5
Page: 315-321
Authors: Claudia I. Muller, Bjorn Ruter, H. Phillip Koeffler and Michael Lubbert

Purine Nucleoside Analogues for the Treatment of Hematological Malignancies: Pharmacology and Clinical Applications

Journal: Current Cancer Drug Targets
Volume: 5,Issue: 6
Page: 421-444
Authors: T. Robak, A. Korycka, M. Kasznicki, A. Wrzesien-Kus and P. Smolewski

Vitamin D Analogs: Mechanism of Action and Therapeutic Applications

Journal: Current Medicinal Chemistry
Volume: 8,Issue: 13
Page: 1661-1679
Authors: Sunil Nagpal, Jianfen Lu and Marcus F. Boehm

New Pharmacological Concepts for the Treatment of Iron Overload Disorders

Journal: Current Medicinal Chemistry
Volume: 16,Issue: 5
Page: 576-590
Authors: Sabine M. Mair and Guenter Weiss

The Combination of Conventional Chemotherapy with New Targeted Therapy in Hematologic Malignancies: The Safety and Efficiency of Low- Dose Cytarabine Supports its Combination with New Therapeutic Agents in Early Clinical Trials

Journal: Current Cancer Therapy Reviews
Volume: 5,Issue: 4
Page: 243-255
Authors: Hanne Fredly, Elisabeth Ersvaer, Camilla Stapnes, Bjorn Tore Gjertsen and Oystein Bruserud

Myeloid Malignancies and the Marrow Microenvironment: Some Recent Studies in Patients with MDS

Journal: Current Cancer Therapy Reviews
Volume: 5,Issue: 4
Page: 310-314
Authors: A. Mario Marcondes, Aravind Ramakrishnan and H. Joachim Deeg

Novel Purine Nucleoside Analogues for Hematological Malignancies

Journal: Recent Patents on Anti-Cancer Drug Discovery
Volume: 3,Issue: 2
Page: 123-136
Authors: Anna Korycka, Ewa Lech-Maranda and Tadeusz Robak

Posaconazole: A New Antifungal Weapon

Journal: Reviews on Recent Clinical Trials
Volume: 6,Issue: 3
Page: 204-219
Authors: Georgios Aperis and Polichronis Alivanis

Development of Cancer Vaccine Targeting WT1 Product which is Expressed in Various Kinds of Malignant Neoplasms

Journal: Medicinal Chemistry Reviews - Online (Discontinued)
Volume: 2,Issue: 6
Page: 447-454
Authors: Y. Oka, A. Tsuboi, O. A. Elisseeva, H. Nakajima, Y. Oji and H. Sugiyama


Approach to New Therapeutics: Investigation by the Use of MDS-derived Cell Lines

Journal: Current Pharmaceutical Design
Volume: 18,Issue: 22
Page: 3204-3214
Authors: Takayuki Tsujioka, Akihito Matsuoka, Yumi Tohyama and Kaoru Tohyama

Optimizing Outcomes Following Allogeneic Hematopoietic Progenitor Cell Transplantation in AML: The Role of Hypomethylating Agents

Journal: Current Cancer Drug Targets
Volume: 13,Issue: 6
Page: 661-669
Authors: Massimo Martino, Roberta Fedele, Tiziana Moscato and Francesca Ronco

Significance of Prion and Prion-Like Proteins in Cancer Development, Progression and Multi-Drug Resistance

Journal: Current Cancer Drug Targets
Volume: 13,Issue: 8
Page: 895-904
Authors: Caroline Hinton, Helma Antony, Saeed M. Hashimi, Alan Munn and Ming Q. Wei

Intramolecular Processes and Their Applications in Prodrugs Approaches- Experimental and Computational Studies

Journal: Current Organic Chemistry
Volume: 20,Issue: 3
Page: 289-315
Authors: Rafik Karaman, Salma Jumaa, Heba Awwadallah, Samya Salah, Yahya Khawaja and Donia Karaman


Eryptosis: Ally or Enemy

Journal: Current Medicinal Chemistry
Volume: 24,Issue: 9
Page: 937-942
Authors: Marilena Briglia, Maria Antonia Rossi and Caterina Faggio

Results 1 - 65 of 65